Cargando…
Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. H...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235815/ https://www.ncbi.nlm.nih.gov/pubmed/34174926 http://dx.doi.org/10.1186/s13046-021-01946-2 |
_version_ | 1783714406992969728 |
---|---|
author | Kemper, Marius Schiecke, Alina Maar, Hanna Nikulin, Sergey Poloznikov, Andrey Galatenko, Vladimir Tachezy, Michael Gebauer, Florian Lange, Tobias Riecken, Kristoffer Tonevitsky, Alexander Aigner, Achim Izbicki, Jakob Schumacher, Udo Wicklein, Daniel |
author_facet | Kemper, Marius Schiecke, Alina Maar, Hanna Nikulin, Sergey Poloznikov, Andrey Galatenko, Vladimir Tachezy, Michael Gebauer, Florian Lange, Tobias Riecken, Kristoffer Tonevitsky, Alexander Aigner, Achim Izbicki, Jakob Schumacher, Udo Wicklein, Daniel |
author_sort | Kemper, Marius |
collection | PubMed |
description | BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. Here we present the first experimental study to investigate if ITGAV plays a functional role in PDA tumor growth and progression with a particular focus on intraperitoneal carcinomatosis. METHODS: Knockdown of ITGAV was generated using an RNA interference-mediated approach in two PDA cell lines. Tumor growth, intraperitoneal and distant metastasis were analyzed in a xenograft model. Cell lines were characterized in vitro. Gene expression of the xenograft tumors was analyzed. Patient samples were histologically classified and associations to survival were evaluated. RESULTS: The knockdown of ITGAV in PDA cells strongly reduces primary tumor growth, peritoneal carcinomatosis and spontaneous pulmonary metastasis. ITGAV activates latent TGF-β and thereby drives epithelial-mesenchymal transition. Combined depletion of ITGAV on the tumor cells and E- and P-selectins in the tumor-host synergistically almost abolishes intraperitoneal spread. Accordingly, high expression of ITGAV in PDA cells was associated with reduced survival in patients. CONCLUSION: Combined depletion of ITGAV in PDA cells and E- and P-selectins in host mice massively suppresses intraperitoneal carcinomatosis of PDA cells xenografted into immunodeficient mice, confirming the hypothesis of a partly redundant adhesion cascade of metastasizing cancer cells. Our data strongly encourage developing novel therapeutic approaches for the combined targeting of E- and P-selectins and ITGAV in PDA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01946-2. |
format | Online Article Text |
id | pubmed-8235815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82358152021-06-28 Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression Kemper, Marius Schiecke, Alina Maar, Hanna Nikulin, Sergey Poloznikov, Andrey Galatenko, Vladimir Tachezy, Michael Gebauer, Florian Lange, Tobias Riecken, Kristoffer Tonevitsky, Alexander Aigner, Achim Izbicki, Jakob Schumacher, Udo Wicklein, Daniel J Exp Clin Cancer Res Research BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. Here we present the first experimental study to investigate if ITGAV plays a functional role in PDA tumor growth and progression with a particular focus on intraperitoneal carcinomatosis. METHODS: Knockdown of ITGAV was generated using an RNA interference-mediated approach in two PDA cell lines. Tumor growth, intraperitoneal and distant metastasis were analyzed in a xenograft model. Cell lines were characterized in vitro. Gene expression of the xenograft tumors was analyzed. Patient samples were histologically classified and associations to survival were evaluated. RESULTS: The knockdown of ITGAV in PDA cells strongly reduces primary tumor growth, peritoneal carcinomatosis and spontaneous pulmonary metastasis. ITGAV activates latent TGF-β and thereby drives epithelial-mesenchymal transition. Combined depletion of ITGAV on the tumor cells and E- and P-selectins in the tumor-host synergistically almost abolishes intraperitoneal spread. Accordingly, high expression of ITGAV in PDA cells was associated with reduced survival in patients. CONCLUSION: Combined depletion of ITGAV in PDA cells and E- and P-selectins in host mice massively suppresses intraperitoneal carcinomatosis of PDA cells xenografted into immunodeficient mice, confirming the hypothesis of a partly redundant adhesion cascade of metastasizing cancer cells. Our data strongly encourage developing novel therapeutic approaches for the combined targeting of E- and P-selectins and ITGAV in PDA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01946-2. BioMed Central 2021-06-26 /pmc/articles/PMC8235815/ /pubmed/34174926 http://dx.doi.org/10.1186/s13046-021-01946-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kemper, Marius Schiecke, Alina Maar, Hanna Nikulin, Sergey Poloznikov, Andrey Galatenko, Vladimir Tachezy, Michael Gebauer, Florian Lange, Tobias Riecken, Kristoffer Tonevitsky, Alexander Aigner, Achim Izbicki, Jakob Schumacher, Udo Wicklein, Daniel Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title | Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title_full | Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title_fullStr | Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title_full_unstemmed | Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title_short | Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression |
title_sort | integrin alpha-v is an important driver in pancreatic adenocarcinoma progression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235815/ https://www.ncbi.nlm.nih.gov/pubmed/34174926 http://dx.doi.org/10.1186/s13046-021-01946-2 |
work_keys_str_mv | AT kempermarius integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT schieckealina integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT maarhanna integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT nikulinsergey integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT poloznikovandrey integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT galatenkovladimir integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT tachezymichael integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT gebauerflorian integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT langetobias integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT rieckenkristoffer integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT tonevitskyalexander integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT aignerachim integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT izbickijakob integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT schumacherudo integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression AT wickleindaniel integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression |